Scope of the Study
Brain implants are the neural implants that directly connected to the brain. These implants electrically stimulate, block or record the signals from the brain. It enables communication between the brain and electronic devices, thus permitting brain activity to be modified, recorded or translated. The purpose of these implants is establishing a biomedical prosthesis circumventing areas in the brain that have become dysfunctional after a stroke or other head injuries.
The market study is being classified by Type (Deep brain stimulator (DBS), Spinal cord stimulator (SCS) and Vagus nerve stimulator (VNS)), by Application (Hospitals, Clinics, Healthcare Facilities and Others) and major geographies with country level break-up.
Boston Scientific Corporation (United States), St Jude Medical (United States), Medtronic (Ireland), Pixium Vision (France), Neuralink (United States), Aleva Neurotherapeutics SA (Switzerland), Nevro Corporation (United States), NeuroPace Inc. (United States), NDI Medical LLC (United States) and Thermo Fisher Scientific Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Terumo Corporation (Japan) and Sapiens Steering Brain Stimulation (Germany).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Brain Implants market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Brain Implants market by Type, Application and Region.
On the basis of geography, the market of Brain Implants has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Neurological Disorders Like Alzheimerís disease
- Rise in Geriatric Population
- Use of Robotic Assistance for Brain Transplant Surgery
- Unavailability of Treatment
- High Cost of the Implant Installation
- Increasing Healthcare Awareness and Technological Advancement
- Brain Implants are Vulnerable to Cyber Attacks
- Legal Issues and Regulations
On 24th January 2019, Boston Scientific Corporation has launched the Vercise Primary Cell and Vercise Gevia, Deep Brain Stimulations (DBS) with directional leads. These new systems are approved by the United States Food and Drug Administration (FDA). These systems designed to allow physicians to control the range, shape, position and direction of electrical stimulation to treat symptoms of Parkinsonís disease.
Key Target AudienceBrain Implant Manufacturers, Regulatory & Government Bodies, Industry Associations, End User Industries and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase